Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With Acute Myeloid Leukemia With Integration of Explorative Multi-omics and ex Vivo Drug Screening Data

NCT05431257 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT05431257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With Acute Myeloid Leukemia With Integration of Explorative Multi-omics and ex Vivo Drug Screening Data
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 2
Overall status
Recruiting
Start date
May 24, 2022
Completion date
September 1, 2031
Enrollment
117 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia